01
Fentanyl
The baseline of drug-checking. Trusted lateral flow detection for the most widespread synthetic opioid in the unregulated supply.
Standard offering
Our Story
Thirty years of building diagnostics that have to work.
Diagnostic Solutions Group has developed custom diagnostic solutions for thirty years. Our work spans complex mass screening for blood banks, individual point-of-care testing, and large-scale global deployments across antibody, molecular, and antigen platforms.
Our partners have included Johnson & Johnson, Pfizer, Novo Nordisk, Abbott Laboratories, Ortho Clinical Diagnostics, and the Red Cross. We have supported national diagnostic deployments for the governments of Nigeria, Côte d'Ivoire, Bangladesh, Liberia, Jamaica, India, and Mali. Our work has reached numerous Broadway productions, hundreds of hospitals and urgent care centers, and a wide range of long-term care facilities.
There is no one-size-fits-all diagnostic. The right answer depends on the pathogen, the venue, the operator, and the workflow. That has been true for performing-arts COVID screening, for in-office differential testing of COVID against influenza, and for dengue screening in rural settings. It is just as true for the harm-reduction work that defines our current focus.
Today the bulk of our development and supply is concentrated on five drug-checking analytes: fentanyl, xylazine, medetomidine, nitazene, and benzodiazepines. We ship them as single-analyte strips or as custom multi-panels assembled to a buyer's specification. We are the only U.S. supplier offering all five from a single source.
Our QA program is aligned to the published academic lot-testing framework from the Lieberman group at Notre Dame and to the AOAC standards released in late 2025 (SMPR 2025.002 and SP 2025.001), the closest thing the harm-reduction strip market has to a community standard. We document and disclose lot QC data with every institutional order. Read the methodology →
Alongside the harm-reduction portfolio we continue to manufacture and ship a rapid antigen test for COVID-19 and influenza A&B for clinic, urgent-care, and turnkey deployment, and a rapid sickle cell screening assay supported by AI-assisted result interpretation, originally developed at a national ministry of health's request as a field-deployable alternative to lab-based hemoglobin electrophoresis.
Our solutions extend beyond the test itself. We provide test interpretation supported by artificial intelligence, AWS-based data management and insights, custom packaging, language translations, custom inserts, and in-person and online training programs.
We are end-to-end supply chain experts, specializing in the import and export of diagnostic tests and reagents. We obtain regulatory approvals, registrations, clearances, and emergency use authorizations. When the product requires it, we provide temperature-controlled logistics.
We are a registered supplier to the United States Government and active in the System for Award Management (SAM). We hold a Commercial and Government Entity (CAGE) Code from the Defense Logistics Agency.